ALMKT:EPA
Mauna Kea Technologies SA
€0.11
arrow_upward
+1.67%(+0.0018) 1D
Oct 21, 5:29:45 PM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALMKT...
Open
€0.11
High
€0.11
Low
€0.11
Mkt. cap
20.23M
Avg. vol.
448.38K
Volume
0.00
P/E ratio
0.93
52-wk high
€0.23
52-wk low
€0.07
EPS
€0.12
Shares outstanding
195.26M
No. of employees
56
Open
€0.11
High
€0.11
Low
€0.11
Mkt. cap
20.23M
Avg. vol.
448.38K
Volume
0.00
P/E ratio
0.93
52-wk high
€0.23
52-wk low
€0.07
EPS
€0.12
Shares outstanding
195.26M
No. of employees
56
News stories
From web sources and news partners
www.tokenpost.com
·
1 hour ago
84% of Early S&P 500 Reporters Beat Q3 Earnings Estimates
Yahoo Finance
·
2 hours ago
S&P 500, Nasdaq Gain, Powered By Meta, Tesla Stock — SPCX, META, TSLA, SKYD, IBM In Focus
StoneX
·
13 hours ago
UAE MSCI and S&P 500 Outlook: Key Levels to Watch
24/7 Wall St.
·
7 hours ago
Johnson & Johnson Raised Its Dividend Every Year. Why Did It Trail the S&P 500?
Profile
Mauna Kea Technologies is a global medical device company focused on endomicroscopy, the field of microscopic imaging during endoscopy procedures. The company researches, develops and markets tools to visualize, detect, and rule out abnormalities including malignant and pre-malignant tumors or lesions in the gastrointestinal and pulmonary tracts.
The company makes Cellvizio, a probe-based Confocal Laser Endomicroscopy system, which provides physicians and researchers with real-time access to histological information during standard endoscopy procedures through high-resolution cellular imaging of internal tissues.
Cellvizio is used in medical applications such as gastrointestinal endoscopy, pulmonology and urology to help physicians diagnose lesions and make accurate treatment decisions in real-time.
Cellvizio went public in July 2011 and trades on the Euronext Paris exchange. Wikipedia
About Mauna Kea Technologies SA